1 active not recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Recurrent Ovarian Serous Adenocarcinoma: new trials by email Literature Review of Recurrent Ovarian Serous Adenocarcinoma trials Research Report on Recurrent Ovarian Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 61 | 2019-12-04 | 2026-08-26 |
Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (1)
Adnexal Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms (2) · Neoplasms by Site (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gonadal Disorders (1) · Ovarian Diseases (1)
Bevacizumab (1) · Disulfides (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · olaparib (1) · pembrolizumab (1) · tremelimumab (1)
National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1)
United States (2)
Emese Zsiros (1) · Sarah F Adams (1)
U10CA180868 (1)